The Experts below are selected from a list of 1821 Experts worldwide ranked by ideXlab platform

Michael E Pichichero - One of the best experts on this subject based on the ideXlab platform.

In-jin Jang - One of the best experts on this subject based on the ideXlab platform.

  • immunogenicity and safety of a single intramuscular dose of a Diphtheria Tetanus Toxoid td vaccine gc1107 in korean adults
    Vaccine, 2011
    Co-Authors: Seung Hwan Lee, Wan Beom Park, Kwang-hee Shin, Dong Ho Ahn, Seo Hyun Yoon, Joo Youn Cho, Sang-goo Shin, In-jin Jang
    Abstract:

    The current study aimed to evaluate immunogenicity and safety of a newly developed Diphtheria-Tetanus Toxoid (Td) vaccine, GC1107 (Green Cross Corporation, Yongin, Korea), in comparison with placebo and active comparator (licensed Td vaccine) in healthy Korean adults. A randomized, double-blind, placebo and active comparator-controlled study was conducted. Forty subjects were randomly administered a single intramuscular dose of GC1107, active comparator or placebo in a ratio of 2:1:1. At 2 and 4 weeks after vaccination, anti-Diphtheria antibody levels in the GC1107 group increased 9.2 and 9.3 times, respectively, compared to predose titers. The corresponding values were 9.3 and 8.3 times for the active comparator group. Anti-Tetanus antibody levels increased 39.0 and 37.9 fold at 2 and 4 weeks, respectively, after GC1107 administration, and 12.2 and 14.7 fold after active comparator administration. No increases in Tetanus or Diphtheria antibody were observed for the placebo group. Adverse events in the GC1107 and active comparator groups were more frequent than for the placebo group, but there were no significant differences between the two active treatments. In conclusion, GC1107 was well tolerated and provided significant boosts of anti-Tetanus and anti-Diphtheria antibodies.

  • Immunogenicity and safety of a single intramuscular dose of a Diphtheria–Tetanus Toxoid (Td) vaccine (GC1107) in Korean adults
    Vaccine, 2011
    Co-Authors: Seung Hwan Lee, Wan Beom Park, Kwang-hee Shin, Dong Ho Ahn, Seo Hyun Yoon, Joo Youn Cho, Sang-goo Shin, In-jin Jang
    Abstract:

    The current study aimed to evaluate immunogenicity and safety of a newly developed Diphtheria-Tetanus Toxoid (Td) vaccine, GC1107 (Green Cross Corporation, Yongin, Korea), in comparison with placebo and active comparator (licensed Td vaccine) in healthy Korean adults. A randomized, double-blind, placebo and active comparator-controlled study was conducted. Forty subjects were randomly administered a single intramuscular dose of GC1107, active comparator or placebo in a ratio of 2:1:1. At 2 and 4 weeks after vaccination, anti-Diphtheria antibody levels in the GC1107 group increased 9.2 and 9.3 times, respectively, compared to predose titers. The corresponding values were 9.3 and 8.3 times for the active comparator group. Anti-Tetanus antibody levels increased 39.0 and 37.9 fold at 2 and 4 weeks, respectively, after GC1107 administration, and 12.2 and 14.7 fold after active comparator administration. No increases in Tetanus or Diphtheria antibody were observed for the placebo group. Adverse events in the GC1107 and active comparator groups were more frequent than for the placebo group, but there were no significant differences between the two active treatments. In conclusion, GC1107 was well tolerated and provided significant boosts of anti-Tetanus and anti-Diphtheria antibodies.

Sandra J Holmes - One of the best experts on this subject based on the ideXlab platform.

  • immunogenicity and safety of a combination Diphtheria Tetanus Toxoid acellular pertussis hepatitis b and inactivated poliovirus vaccine coadministered with a 7 valent pneumococcal conjugate vaccine and a haemophilus influenzae type b conjugate vaccin
    The Journal of Pediatrics, 2007
    Co-Authors: Michael E Pichichero, Henry H Bernstein, Mark M Blatter, Lode Schuerman, Brigitte Cheuvart, Sandra J Holmes
    Abstract:

    Objective To evaluate the immunogenicity and safety of a Diphtheria and Tetanus Toxoids, acellular pertussis, hepatitis B, and inactivated poliovirus-containing vaccine (DTaP-HepB-IPV) coadministered with pneumococcal 7-valent conjugate vaccine (PCV-7) and Haemophilus influenzae type b vaccine (Hib), with separate vaccines concurrently, or staggered (delayed) administration of PCV-7. Study design At 2, 4, and 6 months of age, infants received either DTaP-HepB-IPV plus PCV-7 and Hib (n = 199), separate vaccines (n = 188), or DTaP-HepB-IPV plus Hib with PCV-7 administered 2 weeks later (n = 188). Blood was drawn before and after vaccination. Parents reported symptoms for 4 days after each dose and adverse events throughout the entire study. Results Immunogenicity in the Combination Vaccine Group was noninferior to that of the Separate and Staggered Vaccine Groups with respect to seroprotective rates for Diphtheria, Tetanus, and poliovirus and to geometric mean concentrations for pertussis. Seroprotective rates for HepB and Hib were not different between groups. Seropositivity for PCV-7 was high in all groups. Administration of combination vaccine appeared to be associated with higher rates of irritability, fever ≥100.4°F (38.0°C) and some local symptoms compared with separate vaccines (exploratory P Conclusions DTaP-HepB-IPV was highly immunogenic and well tolerated when coadministered with Hib and PCV-7 at 2, 4, and 6 months of age.

  • safety of a combination Diphtheria Tetanus Toxoid acellular pertussis hepatitis b and inactivated polio vaccine coadministered with a 7 valent pneumococcal conjugate vaccine and a haemophilus influenzae type b conjugate vaccine
    Vaccine, 2007
    Co-Authors: Susan Partridge, Justin C Alvey, Henry H Bernstein, Mark M Blatter, Gerald Bottenfield, Juan M Guerrero, Shelly D Senders, Lode Schuerman, Brigitte Cheuvart, Sandra J Holmes
    Abstract:

    Abstract The safety of DTaP–HepB–IPV vaccine coadministered with PCV and Hib was compared with separate administration of DTaP, HepB, IPV, Hib, and PCV at 2, 4, and 6 months of age. Healthy 2-month-old infants ( N  = 1008) were randomized to the two groups. Following dose 1, there was no significant difference between the groups in the incidence of fever >101.3 °F. After each dose, the incidence of any fever (≥100.4 °F) was significantly higher in the Combination Vaccine Group. The rate of fever >103.1 °F was ≤1.4% in both groups after any of the doses. Medical advice visits for fever were infrequent in both groups (≤1.2%). DTaP–HepB–IPV was safe and well tolerated when coadministered with PCV and Hib.

Robert S Daum - One of the best experts on this subject based on the ideXlab platform.

Seung Hwan Lee - One of the best experts on this subject based on the ideXlab platform.

  • immunogenicity and safety of a single intramuscular dose of a Diphtheria Tetanus Toxoid td vaccine gc1107 in korean adults
    Vaccine, 2011
    Co-Authors: Seung Hwan Lee, Wan Beom Park, Kwang-hee Shin, Dong Ho Ahn, Seo Hyun Yoon, Joo Youn Cho, Sang-goo Shin, In-jin Jang
    Abstract:

    The current study aimed to evaluate immunogenicity and safety of a newly developed Diphtheria-Tetanus Toxoid (Td) vaccine, GC1107 (Green Cross Corporation, Yongin, Korea), in comparison with placebo and active comparator (licensed Td vaccine) in healthy Korean adults. A randomized, double-blind, placebo and active comparator-controlled study was conducted. Forty subjects were randomly administered a single intramuscular dose of GC1107, active comparator or placebo in a ratio of 2:1:1. At 2 and 4 weeks after vaccination, anti-Diphtheria antibody levels in the GC1107 group increased 9.2 and 9.3 times, respectively, compared to predose titers. The corresponding values were 9.3 and 8.3 times for the active comparator group. Anti-Tetanus antibody levels increased 39.0 and 37.9 fold at 2 and 4 weeks, respectively, after GC1107 administration, and 12.2 and 14.7 fold after active comparator administration. No increases in Tetanus or Diphtheria antibody were observed for the placebo group. Adverse events in the GC1107 and active comparator groups were more frequent than for the placebo group, but there were no significant differences between the two active treatments. In conclusion, GC1107 was well tolerated and provided significant boosts of anti-Tetanus and anti-Diphtheria antibodies.

  • Immunogenicity and safety of a single intramuscular dose of a Diphtheria–Tetanus Toxoid (Td) vaccine (GC1107) in Korean adults
    Vaccine, 2011
    Co-Authors: Seung Hwan Lee, Wan Beom Park, Kwang-hee Shin, Dong Ho Ahn, Seo Hyun Yoon, Joo Youn Cho, Sang-goo Shin, In-jin Jang
    Abstract:

    The current study aimed to evaluate immunogenicity and safety of a newly developed Diphtheria-Tetanus Toxoid (Td) vaccine, GC1107 (Green Cross Corporation, Yongin, Korea), in comparison with placebo and active comparator (licensed Td vaccine) in healthy Korean adults. A randomized, double-blind, placebo and active comparator-controlled study was conducted. Forty subjects were randomly administered a single intramuscular dose of GC1107, active comparator or placebo in a ratio of 2:1:1. At 2 and 4 weeks after vaccination, anti-Diphtheria antibody levels in the GC1107 group increased 9.2 and 9.3 times, respectively, compared to predose titers. The corresponding values were 9.3 and 8.3 times for the active comparator group. Anti-Tetanus antibody levels increased 39.0 and 37.9 fold at 2 and 4 weeks, respectively, after GC1107 administration, and 12.2 and 14.7 fold after active comparator administration. No increases in Tetanus or Diphtheria antibody were observed for the placebo group. Adverse events in the GC1107 and active comparator groups were more frequent than for the placebo group, but there were no significant differences between the two active treatments. In conclusion, GC1107 was well tolerated and provided significant boosts of anti-Tetanus and anti-Diphtheria antibodies.